Bruce Spohler
Analyst · KBW. Ryan your line is open
Thank you, Rich. Overall, the financial health of our portfolio companies remained sound, reflecting our disciplined underwriting and continued focus on downside protection. At September 30th, the weighted average investment and risk rating of our portfolio was 1.9 based on our 1:4 risk rating scale with 1 representing the least amount of risk. As further indication of the strong fundamentals of our portfolio, only 3% of our portfolio was on watchlist status at quarter-end and 100% of our portfolio was performing at quarter-end. Our $1.7 billion comprehensive portfolio encompasses 230 distinct issuers across 92 industries. The average investment per issuer was $7.4 million or 0.4% highly diversified. Also at quarter-end, over 98% of our portfolio consisted of senior secured loans comprised of approximately 83% first lien loans and 14% second lien loans. We continue to reduce our exposure to second lien loans, which carry higher yields and higher risk than our first lien investments. Yet, the weighted average yield of our overall portfolio increased to 11.2% at quarter-end compared to 10.9% in Q2. Importantly, through our niche commercial finance verticals, we've been able to maintain this 11% asset level yield in spite of the spread compression we are all seeing cash flow lending. We've done this by replacing our second lien cash flow loans with lower risk yet higher return first lien asset based investments. Including activity across our four business lines, originations totaled just over $200 million and repayments were approximately $280 million, resulting in net comprehensive portfolio reduction of approximately $80 million. Given the continued heated cash flow market conditions, we intentionally allow that segment to shrink. The decline in our cash flow loan portfolio was partially offset by growth in our asset based strategies, which currently offer a much more favorable risk and return profile. Let me now provide a brief update on each of our four verticals. Our cash flow business invest in senior secured loans, predominantly first lien and stretched first lien investments to upper middle market companies with an average EBITDA on our portfolio of approximately $70 million. During the third quarter, we originated cash flow investments of approximately $45 million, all of which were first lien loans. And we had repayments of approximately $165 million in our cash flow segment. The reduction in this portfolio was the direct decision -- result of our decision to not participate in many of the refinancings of our incumbent investments due to pricing and structure degradation, resulting in loan terms that did not meet our investment criteria. At quarter-end, our cash flow loan portfolio was approximately $500 million, representing approximately 30% of our total portfolio. Our exposure to second lean loans has declined to under 15%, down from 35% at the beginning of the year. We expect to see a continued reduction in our second lien exposure over the coming quarters. At September 30th, the weighted average trailing 12 month revenue and EBITDA of our borrowers grew in the high single-digits, reflecting continued positive fundamental trends at the portfolio companies. On a fair weighted base average basis, the leverage through our investment was just over 5 times and interest coverage was just over 2.25 quarter times. In addition, the weighted average yield of our cash flow portfolio is 9.8% compared to 9.6% in the prior quarter. With the addition of the newly raised capital that Michael discussed, SLRC is already benefiting from Solar Capital Partners' increased scale and ability to be a full solutions provider. As an example, we were recently able to support Abry Partners' refinancing of Aegis Toxicology Sciences, which was an existing SLRC portfolio company where we had held a second lien investment. We almost doubled our total dollars to $65 million and moved up the capital structure to a first lien investment. Now, let me turn to our asset based lending, Crystal Finance platform. These loans, as a reminder, are made against the realizable liquidation value of the portfolio companies; assets and are accompanied by meaningful upfront and prepayment fees. During the third quarter, we funded $63 million of new asset based investments and had repayments of approximately $40 million, resulting in just over $20 million of asset based lending portfolio growth. At 9/30, the senior secured asset-based loan portfolio was approximately $590 million, representing approximately 35% of our total portfolio. The weighted average yield was 12.3% consistent with the prior quarter. This platform paid Solar Capital a dividend of $7.5 million equating to 10.7% yield on cost. Moving on to our equipment finance business. Solar, as you know, enter this business through the acquisition of Nations Equipment, which was founded in 2010 by former GE senior executives. Included in this business, our equipment financings held on Solar balance sheet, as well as those that are held in net holdings, a 100% owned portfolio companies that we utilize for tax efficiency. Through the third quarter, NEF had new investments of just over $16 million and had repayments totaling $44 million. Our NEF equipment finance strategy has a total portfolio of just over $375 million, which represents a 15% increase since our acquisition just about a year ago. Portfolio consists of loans to 147 distinct barrowers with an average issuer exposure of approximately $2.6 million. In total, the equipment finance portfolio represents 22% of our combined portfolio. 100% of NEF's investments are in first lien loans and approximately 97% fixed rate. Here we mitigate interest rate risk through both the relatively short holding period of NEF's assets, as well as our efforts to match fund the fixed rate nature with our unsecured fixed rate liabilities of approximately $250 million on Solar's balance sheet. The weighted average yield of the equipment finance portfolio was 11.2% compared to 10.5% the prior quarter. Finally, let me provide an update on our life science lending business. As a quick reminder, these are first lien senior secured loans and typically are accompanied by either a success fee or a warrant. During the third quarter, the team originated just over $30 million of loans and had repayments of approximately $34 million. Our life science loan portfolio totals just over $200 million across 18 issuers with an average investment of just over $11 million. In totality, life science loans represent 12% of our comprehensive portfolio. The weighted average yield in this portfolio was 11.6%, excluding success fees and warrants. As Michael mentioned, the middle market cash flow lending environment remains extremely frothy. We benefit greatly from our diversified origination sources across not only cash flow but also asset based lending verticals. Now with our increased scale provides us an even greater competitive advantage across these business lines. We will, however, continue to be prudent and highly disciplined in deploying our substantial available capital. At this time, I'll turn the call back to Michael.